07
Jul

The FDA has provided its special ‘breakthrough’ status for Novartis’ closely-watched development program for a personalized CAR-T cancer therapy, promising to help speed development for engineered T cells.

…read more

Source: Novartis’ leading CAR-T cancer therapy gains ‘breakthrough’ status at the FDA

    

0 No comments